More recently, bombesin analogues have been supplanted by prostate-specific membrane antigen (PSMA)-targeting agents in prostate cancer imaging, culminating in the NDA approval for [68Ga]Ga-PSMA-11 [114,115,116]. The gene discussed is FOLH1; the disease is prostate cancer.